Auteurs
Curation
Istex
Racine
Curation
Checkpoint
Istex
Racine
Istex
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Curation (Istex)

Index « Auteurs » - entrée « J. Sibilia »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
J. Shim < J. Sibilia < J. Siblia  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 9.
Ident.Authors (with country if any)Title
000850 (2013) A. Östör [Royaume-Uni] ; J. A. Román Ivorra [Espagne] ; J. Wollenhaupt [Allemagne] ; C. Mpofu [Suisse] ; C. Bernasconi [Suisse] ; J. Sibilia [France] ; V. Bykerk [États-Unis, Canada]FRI0179 Comparison of tocilizumab as monotherapy or in combination with non-biological disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) and an inadequate response to anti-TNF agents
000B64 (2013) S. Godot [France] ; J. E. Gottenberg [France] ; S. Paternotte ; I. Pane [France] ; B. Combe [France] ; J. Sibilia [France] ; R.-M. Flipo ; T. Schaeverbeke ; P. Ravaud [France] ; E. Toussirot ; F. Berenbaum [France] ; X. Mariette [France] ; D. Wendling ; J. Sellam [France]THU0122 Safety of surgery in patients with rheumatoid arthritis treated by rituximab in routine care: Data from the french air registry
000D84 (2013) A. Meyer [France] ; G. Lefevre ; A. Tournadre ; B. Le Goff ; S. Ottaviani [France] ; A.-L. Buchdahl ; M. De Brandt [France] ; P. Coquerelle [France] ; R.-M. Flipo ; G. Falgarone [France] ; G. Bernard [France] ; Z. Amoura [France] ; O. Benveniste [France] ; J. Sibilia [France] ; E. Hachulla ; B. Hervier [France]FRI0381 During antisynthetase syndrome, anti-citrullinated peptides are a marker of severe joint disease
001203 (2012) J E Gottenberg [France] ; P. Ravaud [France] ; A. Cantagrel [France] ; B. Combe [France] ; R M Flipo [France] ; T. Schaeverbeke [France] ; E. Houvenagel [France] ; P. Gaudin [France] ; D. Loeuille [France] ; S. Rist [France] ; M. Dougados [France] ; J. Sibilia [France] ; X. Le Loët [France] ; C. Marcelli [France] ; T. Bardin [France] ; I. Pane [France] ; G. Baron [France] ; X. Mariette [France]Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry
001321 (2013) J. H. Salmon ; P. Ravaud [France] ; T. Bardin ; P. Cacoub [France] ; A. Cantagruel [France] ; B. Combe [France] ; M. Dougados [France] ; R.-M. Flipo ; B. Godeau ; L. Guillevin [France] ; X. Le Loët ; E. Hachulla ; T. Schaeverbeke ; J. Sibilia [France] ; I. Pane [France] ; G. Baron ; X. Mariette [France] ; J.-E. Gottenberg [France]FRI0246 Serious infusion-related reactions after rituximab in patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry
001352 (2013) A. Meyer [France] ; A. Theulin ; E. Chatelus ; C. Sordet ; R.-M. Javier ; B. Geny [France] ; J.-E. Gottenberg ; J. SibiliaTHU0412 Reactive hyperemia index (RHI) is associated with macrovascular disease and lung disease in systemic sclerosis
001367 (2013) J. Sellam [France] ; S. Rouanet ; H. Hendel-Chavez ; S. Marion-Thore [France] ; C. Miceli-Richard ; B. Combe [France] ; J. Sibilia [France] ; X. Le Loët ; J. Tebib ; G. Chiocchia [France] ; R. Jourdan ; M. Dougados [France] ; Y. Taoufik ; X. MarietteFRI0247 Serum level of interleukin 33, a novel independent predictive biomarker of clinical response to rituximab in rheumatoid arthritis: results from the smart trial
001405 (2013) A. Frazier-Mironer [France] ; A. Cantagrel [France] ; B. Combe [France] ; V. Deschamps ; M. Dougados [France] ; R.-M. Flipo ; I. Logeart ; X. Mariette ; T. Schaeverbeke ; J. Sibilia [France] ; X. Le Loët [France]THU0173 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study
001415 (2012) A. Ruyssen-Witrand [France] ; S. Rouanet [France] ; B. Combe [France] ; M. Dougados [France] ; X. Le Loët [France] ; J. Sibilia [France] ; J. Tebib [France] ; X. Mariette [France] ; A. Constantin [France]Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/Author.i -k "J. Sibilia" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/Author.i  \
                -Sk "J. Sibilia" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    Author.i
   |clé=    J. Sibilia
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021